DealsJun 15, 2026, 07:06 AM
Lifecore Secures 7th Late-Stage Program Agreement in 7 Months
AI Summary
Lifecore Biomedical announced a new agreement with a global pharmaceutical company for technical transfer and commercial manufacturing of an injectable suspension product for neurological disorders. This significant win marks the seventh late-stage program agreement for Lifecore in the past seven months, demonstrating strong business development momentum. The agreement underscores confidence in Lifecore's technical expertise in producing higher-viscosity and complex pharmaceutical products, positioning them as a valuable partner for multinational pharmaceutical companies.
Key Highlights
- Lifecore signed a new agreement with a global pharmaceutical company.
- The agreement is for technical transfer and commercial manufacturing of an injectable neurology product.
- This marks Lifecore's seventh agreement for a late-stage program in the last seven months.
- The product is a higher-viscosity suspension formulation for neurological disorders.
- The deal highlights increasing demand for specialized manufacturing expertise for complex pharmaceutical products.
Price Impact
More from LFCR